Market
Thiamine mononitrate (vitamin B1 source) in Mexico is primarily an import-dependent micronutrient ingredient used by manufacturers of dietary supplements, fortified foods, and nutrition premixes. Mexico regulates “suplementos alimenticios” under the Reglamento de Control Sanitario de Productos y Servicios (RCSPyS), including restrictions on therapeutic claims and specific daily maximum limits for certain vitamins. For finished dietary supplements, COFEPRIS indicates imports require a Permiso Sanitario Previo de Importación (PSPI) and the authority reviews labeling and ingredients as part of the permit process. Market access risk is driven more by regulatory classification, labeling/claims, and documentary compliance than by agricultural seasonality or domestic production constraints.
Market RoleNet importer (import-dependent ingredient market)
Domestic RoleDownstream manufacturing and consumption market for supplements/fortified products using imported thiamine mononitrate as an input
Risks
Regulatory Compliance HighMexico’s supplement framework (RCSPyS) restricts therapeutic/disease claims and indicates products with recognized pharmacological action or attributed therapeutic/preventive/rehabilitative properties cannot be marketed as supplements (unless compliant as regulated health inputs), creating a high risk of import denial, detention, or forced relabeling/reclassification if claims/positioning are not aligned.Align product positioning, labeling, and marketing claims with the RCSPyS supplement restrictions; pre-review Spanish labels and claims with qualified regulatory counsel and confirm the correct COFEPRIS import pathway (PSPI vs. other health input permits) before shipment.
Regulatory Compliance MediumFor finished dietary supplements, COFEPRIS indicates imports require a PSPI and the authority reviews labeling and ingredients; incomplete or inconsistent dossiers (label, ingredient list, or supporting certificates/analyses) can cause delays or rejection.Build a shipment-level compliance pack (label artwork, full ingredient specification, COA by lot, and any certificates required by the PSPI modality) and run a pre-submission checklist aligned to the COFEPRIS PSPI procedure.
Product Safety MediumRCSPyS includes daily maximum limits for certain vitamins in supplements (including vitamin B1) and requires that supplements not present chemical/biological contaminants that can put consumer health at risk, increasing enforcement exposure if formulation dosing or impurity controls are weak.Control formulation on a thiamine-equivalent basis and maintain robust incoming QC (identity, assay, and impurity screening) with retained samples and auditable records.
Documentation Gap LowMisalignment between the tariff fraction/regulatory category and the intended use (ingredient vs. finished supplement) can cause avoidable regulatory holds because requirements differ by classification and pathway.Confirm the tariff fraction and applicable RRNA via SIAVI/TIGIE and map it to the correct COFEPRIS procedure (and VUCEM workflow) before contracting freight.
FAQ
Is there a Mexico-specific maximum daily amount for vitamin B1 in dietary supplements?Yes. Mexico’s Reglamento de Control Sanitario de Productos y Servicios (RCSPyS) includes a daily maximum limit for vitamin B1 (thiamine) in “suplementos alimenticios” of 15 mg/day. If you use thiamine mononitrate as the source, the formula should be calculated on a thiamine-equivalent basis to stay within that limit.
Do dietary supplements require an import permit in Mexico?COFEPRIS states that dietary supplements require a Permiso Sanitario Previo de Importación (PSPI) and that COFEPRIS reviews the product’s labeling and ingredients as part of issuing the permit. COFEPRIS also describes different PSPI modalities (products, return, and samples/personal consumption).
What kinds of claims can trigger problems for supplements in Mexico?Under RCSPyS, supplements must not use misleading presentation and must avoid disease-related or therapeutic/preventive/rehabilitative claims. RCSPyS also indicates that products with recognized pharmacological action or attributed therapeutic properties cannot be commercialized as supplements unless they comply with the rules applicable to regulated health inputs.